Sevenfact (eptacog beta) is a bypassing agent that’s approved to treat bleeding episodes in people with hemophilia A or hemophilia B who developed inhibitors, or neutralizing antibodies, against clotting factor VIII (FVIII) or factor IX (FIX).

Eloctate (efmoroctocog alfa) is an extended half-life therapy that's approved to prevent and treat bleeds, including those occurring during surgery, in adults and children with hemophilia A.

While hemophilia A and hemophilia B are both bleeding disorders characterized by deficiencies in blood clotting factors, there are differences in one type versus the other, particularly in the specific genetic mutations that cause the disease, and in some of the treatment methods.

Hemophilia C is a rare bleeding disorder that affects the blood’s ability to clot.

Hemophilia B is a rare genetic bleeding disorder that impairs the blood’s ability to clot properly.

BeneFIX (nonacog alfa) is a recombinant, or man-made, clotting factor therapy approved to prevent and treat bleeding episodes, including those occurring during surgery, in adults and children with hemophilia B.

Hemophilia A is a rare genetic disorder that affects the blood’s ability to clot properly. It is the most common form of hemophilia, responsible for 80% of all cases.